Company Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

Latest News

Hankook iON Race Handles Tokyo's Day-to-Night Transition Across Two Races

PR Newswire • 07/27/2026

Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader

PR Newswire • 07/27/2026

Earnings To Watch: First Commonwealth Financial (FCF) Reports Q2 Results Tomorrow

StockStory • 07/27/2026

Oil slips 4% after US, Iran pause fighting over weekend

Reuters • 07/27/2026

This Quantum Stock Is a Key Nvidia Partner and Looks Like a Buy Near a 52-Week Low

Motley Fool • 07/27/2026